Global Bladder Cancer Targeted Drug market growth is projected to reach  US$ 957 million in 2025 to US$ 1653 million in 2031; it is expected to grow at a CAGR of 9.5% from 2025 to 2031.

Global Bladder Cancer Targeted Drug Market Trends and Analysis 2025-31

The global Bladder Cancer Targeted Drug market size is predicted to grow from US$ 957 million in 2025 to US$ 1653 million in 2031; it is expected to grow at a CAGR of 9.5% from 2025 to 2031. Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. Targeted therapy is a treatment that targets the cancers specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells and tries to limit damage to healthy cells. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. LPI (LP Information) newest research report, the Bladder Cancer Targeted Drug Industry Forecast looks at past sales and reviews total world Bladder Cancer Targeted Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Bladder Cancer Targeted Drug sales for 2025 through 2031. With Bladder Cancer Targeted Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bladder Cancer Targeted Drug industry. This Insight Report provides a comprehensive analysis of the global Bladder Cancer Targeted Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Bladder Cancer Targeted Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Bladder Cancer Targeted Drug market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bladder Cancer Targeted Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bladder Cancer Targeted Drug. This report presents a comprehensive overview, market shares, and growth opportunities of Bladder Cancer Targeted Drug market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Atezolizumab (Tecentriq) &nbsp;&nbsp;&nbsp; Avelumab (Bavencio) &nbsp;&nbsp;&nbsp; Erdafitinib (Balversa) &nbsp;&nbsp;&nbsp; Other Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Retail Pharmacy &nbsp;&nbsp;&nbsp; Other This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Pfizer &nbsp;&nbsp;&nbsp; Merck KGaA &nbsp;&nbsp;&nbsp; Roche &nbsp;&nbsp;&nbsp; Astellas &nbsp;&nbsp;&nbsp; Janssen Biotech &nbsp;&nbsp;&nbsp; Bristol-Myers Squibb &nbsp;&nbsp;&nbsp; Merck & Co. &nbsp;&nbsp;&nbsp; Gilead Sciences

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Bladder Cancer Targeted Drug Market Size (2020-2031) &nbsp;2.1.2 Bladder Cancer Targeted Drug Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for Bladder Cancer Targeted Drug by Country/Region (2020, 2024 & 2031) &nbsp;2.2 Bladder Cancer Targeted Drug Segment by Type &nbsp;2.2.1 Atezolizumab (Tecentriq) &nbsp;2.2.2 Avelumab (Bavencio) &nbsp;2.2.3 Erdafitinib (Balversa) &nbsp;2.2.4 Other &nbsp;2.3 Bladder Cancer Targeted Drug Market Size by Type &nbsp;2.3.1 Bladder Cancer Targeted Drug Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global Bladder Cancer Targeted Drug Market Size Market Share by Type (2020-2025) &nbsp;2.4 Bladder Cancer Targeted Drug Segment by Application &nbsp;2.4.1 Hospital &nbsp;2.4.2 Retail Pharmacy &nbsp;2.4.3 Other &nbsp;2.5 Bladder Cancer Targeted Drug Market Size by Application &nbsp;2.5.1 Bladder Cancer Targeted Drug Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global Bladder Cancer Targeted Drug Market Size Market Share by Application (2020-2025) 3 Bladder Cancer Targeted Drug Market Size by Player &nbsp;3.1 Bladder Cancer Targeted Drug Market Size Market Share by Player &nbsp;3.1.1 Global Bladder Cancer Targeted Drug Revenue by Player (2020-2025) &nbsp;3.1.2 Global Bladder Cancer Targeted Drug Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global Bladder Cancer Targeted Drug Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 Bladder Cancer Targeted Drug by Region &nbsp;4.1 Bladder Cancer Targeted Drug Market Size by Region (2020-2025) &nbsp;4.2 Global Bladder Cancer Targeted Drug Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Bladder Cancer Targeted Drug Market Size Growth (2020-2025) &nbsp;4.4 APAC Bladder Cancer Targeted Drug Market Size Growth (2020-2025) &nbsp;4.5 Europe Bladder Cancer Targeted Drug Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa Bladder Cancer Targeted Drug Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas Bladder Cancer Targeted Drug Market Size by Country (2020-2025) &nbsp;5.2 Americas Bladder Cancer Targeted Drug Market Size by Type (2020-2025) &nbsp;5.3 Americas Bladder Cancer Targeted Drug Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Bladder Cancer Targeted Drug Market Size by Region (2020-2025) &nbsp;6.2 APAC Bladder Cancer Targeted Drug Market Size by Type (2020-2025) &nbsp;6.3 APAC Bladder Cancer Targeted Drug Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe Bladder Cancer Targeted Drug Market Size by Country (2020-2025) &nbsp;7.2 Europe Bladder Cancer Targeted Drug Market Size by Type (2020-2025) &nbsp;7.3 Europe Bladder Cancer Targeted Drug Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Bladder Cancer Targeted Drug by Region (2020-2025) &nbsp;8.2 Middle East & Africa Bladder Cancer Targeted Drug Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa Bladder Cancer Targeted Drug Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global Bladder Cancer Targeted Drug Market Forecast &nbsp;10.1 Global Bladder Cancer Targeted Drug Forecast by Region (2026-2031) &nbsp;10.1.1 Global Bladder Cancer Targeted Drug Forecast by Region (2026-2031) &nbsp;10.1.2 Americas Bladder Cancer Targeted Drug Forecast &nbsp;10.1.3 APAC Bladder Cancer Targeted Drug Forecast &nbsp;10.1.4 Europe Bladder Cancer Targeted Drug Forecast &nbsp;10.1.5 Middle East & Africa Bladder Cancer Targeted Drug Forecast &nbsp;10.2 Americas Bladder Cancer Targeted Drug Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market Bladder Cancer Targeted Drug Forecast &nbsp;10.2.2 Canada Market Bladder Cancer Targeted Drug Forecast &nbsp;10.2.3 Mexico Market Bladder Cancer Targeted Drug Forecast &nbsp;10.2.4 Brazil Market Bladder Cancer Targeted Drug Forecast &nbsp;10.3 APAC Bladder Cancer Targeted Drug Forecast by Region (2026-2031) &nbsp;10.3.1 China Bladder Cancer Targeted Drug Market Forecast &nbsp;10.3.2 Japan Market Bladder Cancer Targeted Drug Forecast &nbsp;10.3.3 Korea Market Bladder Cancer Targeted Drug Forecast &nbsp;10.3.4 Southeast Asia Market Bladder Cancer Targeted Drug Forecast &nbsp;10.3.5 India Market Bladder Cancer Targeted Drug Forecast &nbsp;10.3.6 Australia Market Bladder Cancer Targeted Drug Forecast &nbsp;10.4 Europe Bladder Cancer Targeted Drug Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market Bladder Cancer Targeted Drug Forecast &nbsp;10.4.2 France Market Bladder Cancer Targeted Drug Forecast &nbsp;10.4.3 UK Market Bladder Cancer Targeted Drug Forecast &nbsp;10.4.4 Italy Market Bladder Cancer Targeted Drug Forecast &nbsp;10.4.5 Russia Market Bladder Cancer Targeted Drug Forecast &nbsp;10.5 Middle East & Africa Bladder Cancer Targeted Drug Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market Bladder Cancer Targeted Drug Forecast &nbsp;10.5.2 South Africa Market Bladder Cancer Targeted Drug Forecast &nbsp;10.5.3 Israel Market Bladder Cancer Targeted Drug Forecast &nbsp;10.5.4 Turkey Market Bladder Cancer Targeted Drug Forecast &nbsp;10.6 Global Bladder Cancer Targeted Drug Forecast by Type (2026-2031) &nbsp;10.7 Global Bladder Cancer Targeted Drug Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market Bladder Cancer Targeted Drug Forecast 11 Key Players Analysis &nbsp;11.1 Pfizer &nbsp;11.1.1 Pfizer Company Information &nbsp;11.1.2 Pfizer Bladder Cancer Targeted Drug Product Offered &nbsp;11.1.3 Pfizer Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 Pfizer Main Business Overview &nbsp;11.1.5 Pfizer Latest Developments &nbsp;11.2 Merck KGaA &nbsp;11.2.1 Merck KGaA Company Information &nbsp;11.2.2 Merck KGaA Bladder Cancer Targeted Drug Product Offered &nbsp;11.2.3 Merck KGaA Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Merck KGaA Main Business Overview &nbsp;11.2.5 Merck KGaA Latest Developments &nbsp;11.3 Roche &nbsp;11.3.1 Roche Company Information &nbsp;11.3.2 Roche Bladder Cancer Targeted Drug Product Offered &nbsp;11.3.3 Roche Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 Roche Main Business Overview &nbsp;11.3.5 Roche Latest Developments &nbsp;11.4 Astellas &nbsp;11.4.1 Astellas Company Information &nbsp;11.4.2 Astellas Bladder Cancer Targeted Drug Product Offered &nbsp;11.4.3 Astellas Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 Astellas Main Business Overview &nbsp;11.4.5 Astellas Latest Developments &nbsp;11.5 Janssen Biotech &nbsp;11.5.1 Janssen Biotech Company Information &nbsp;11.5.2 Janssen Biotech Bladder Cancer Targeted Drug Product Offered &nbsp;11.5.3 Janssen Biotech Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 Janssen Biotech Main Business Overview &nbsp;11.5.5 Janssen Biotech Latest Developments &nbsp;11.6 Bristol-Myers Squibb &nbsp;11.6.1 Bristol-Myers Squibb Company Information &nbsp;11.6.2 Bristol-Myers Squibb Bladder Cancer Targeted Drug Product Offered &nbsp;11.6.3 Bristol-Myers Squibb Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 Bristol-Myers Squibb Main Business Overview &nbsp;11.6.5 Bristol-Myers Squibb Latest Developments &nbsp;11.7 Merck & Co. &nbsp;11.7.1 Merck & Co. Company Information &nbsp;11.7.2 Merck & Co. Bladder Cancer Targeted Drug Product Offered &nbsp;11.7.3 Merck & Co. Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.7.4 Merck & Co. Main Business Overview &nbsp;11.7.5 Merck & Co. Latest Developments &nbsp;11.8 Gilead Sciences &nbsp;11.8.1 Gilead Sciences Company Information &nbsp;11.8.2 Gilead Sciences Bladder Cancer Targeted Drug Product Offered &nbsp;11.8.3 Gilead Sciences Bladder Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.8.4 Gilead Sciences Main Business Overview &nbsp;11.8.5 Gilead Sciences Latest Developments 12 Research Findings and Conclusion

Report	Global Bladder Cancer Targeted Drug Market Growth (Status and Outlook) 2025-2031
Selected License	Multi ID: LPI13699

Buyer Information

Order Summary